Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda Ahn

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Clinical Journal of Oncology Nursing|September 15, 2022
Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung CancerLinda Ahn, Terri Alexander, Soetkin Vlassak, et al.
Sarcoma|April 3, 2014
Consumptive coagulopathy in angiosarcoma: a recurrent phenomenon?Mohamad Farid, Linda Ahn, Andrew Brohl, et al.
The Oncologist|January 29, 2014
Malignant peripheral nerve sheath tumorsMohamad Farid, Elizabeth G Demicco, Roberto Garcia, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomasJuliana B Schilsky, Ai Ni, Linda Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2011
Activity of Sorafenib against desmoid tumor/deep fibromatosisMrinal M Gounder, Robert A Lefkowitz, Mary Louise Keohan, et al.
JCO Precision Oncology|July 12, 2021
Erlotinib and Trametinib in Patients With <i>EGFR</i>-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase InhibitorJia Luo, Alex Makhnin, Yosef Tobi, et al.
Cancer|September 24, 2017
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastasesKathryn C Arbour, Mark G Kris, Gregory J Riely, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2022
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228Paul K Paik, Pang-Dian Fan, Besnik Qeriqi, et al.
Nature Communications|October 14, 2022
Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomasPaul K Paik, Jia Luo, Ni Ai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2020
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung CancersPaul K Paik, Rachel K Kim, Linda Ahn, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Clinical Journal of Oncology Nursing|September 15, 2022
Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung CancerLinda Ahn, Terri Alexander, Soetkin Vlassak, et al.
Sarcoma|April 3, 2014
Consumptive coagulopathy in angiosarcoma: a recurrent phenomenon?Mohamad Farid, Linda Ahn, Andrew Brohl, et al.
The Oncologist|January 29, 2014
Malignant peripheral nerve sheath tumorsMohamad Farid, Elizabeth G Demicco, Roberto Garcia, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomasJuliana B Schilsky, Ai Ni, Linda Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2011
Activity of Sorafenib against desmoid tumor/deep fibromatosisMrinal M Gounder, Robert A Lefkowitz, Mary Louise Keohan, et al.
JCO Precision Oncology|July 12, 2021
Erlotinib and Trametinib in Patients With <i>EGFR</i>-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase InhibitorJia Luo, Alex Makhnin, Yosef Tobi, et al.
Cancer|September 24, 2017
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastasesKathryn C Arbour, Mark G Kris, Gregory J Riely, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2022
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228Paul K Paik, Pang-Dian Fan, Besnik Qeriqi, et al.
Nature Communications|October 14, 2022
Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomasPaul K Paik, Jia Luo, Ni Ai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2020
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung CancersPaul K Paik, Rachel K Kim, Linda Ahn, et al.
Pageof 2